Hyperpolarized 13C Metabolic MRI of the Human Heart: Initial Experience

Rationale: Altered cardiac energetics is known to play an important role in the progression toward heart failure. A noninvasive method for imaging metabolic markers that could be used in longitudinal studies would be useful for understanding therapeutic approaches that target metabolism.

Objective: To demonstrate the first hyperpolarized ¹³C metabolic magnetic resonance imaging of the human heart.

Methods and results: Four healthy subjects underwent conventional proton cardiac magnetic resonance imaging followed by ¹³C imaging and spectroscopic acquisition immediately after intravenous administration of a 0.1 mmol/kg dose of hyperpolarized [1-¹³C]pyruvate. All subjects tolerated the procedure well with no adverse effects reported ≤1 month post procedure. The [1-¹³C]pyruvate signal appeared within the chambers but not within the muscle. Imaging of the downstream metabolites showed ¹³C-bicarbonate signal mainly confined to the left ventricular myocardium, whereas the [1-¹³C]lactate signal appeared both within the chambers and in the myocardium. The mean ¹³C image signal:noise ratio was 115 for [1-¹³C]pyruvate, 56 for ¹³C-bicarbonate, and 53 for [1-¹³C]lactate.

Conclusions: These results represent the first ¹³C images of the human heart. The appearance of ¹³C-bicarbonate signal after administration of hyperpolarized [1-¹³C]pyruvate was readily detected in this healthy cohort (n=4). This shows that assessment of pyruvate metabolism in vivo in humans is feasible using current technology.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02648009.